THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Graham, Donna M. [1 ]
Djalalov, Sandjar [2 ]
Beca, Jaclyn [2 ]
Hoch, Jeffrey [3 ]
Tsao, Ming S. [4 ]
Cutz, Jc [5 ]
Leighl, Natasha [1 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, East Melbourne, Vic, Australia
[2] Canc Care Ontario, Pharmacoecon Res Unit, Toronto, ON, Canada
[3] Canc Care Ontarior Pharmacoecon Unit, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Dept Pathol, East Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON L8S 4L8, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
cost-effectiveness; ALK-rearrangement; Crizotinib; advanced non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.24-037
引用
收藏
页码：S1317 / S1318
页数：2
相关论文
共 50 条
  • [31] EML4-ALK Fusion Subtype Is Associated with Therapeutic Efficacy in Advanced Non-Small Cell Lung Cancer
    Wang, H.
    Li, H.
    Ma, J.
    Yan, X.
    Li, P.
    Zhang, M.
    Zhang, X.
    Zhang, G.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S847 - S847
  • [32] ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK
    Sun, Yunguang
    Nowak, Kamila A.
    Zaorsky, Nicholas G.
    Winchester, Chia-Lin
    Dalal, Kunal
    Giacalone, Nicholas J.
    Liu, Ningbo
    Werner-Wasik, Maria
    Wasik, Mariusz A.
    Dicker, Adam P.
    Lu, Bo
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05) : 696 - 704
  • [33] Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
    Franchi, Matteo
    Pellegrini, Giacomo
    Corrao, Giovanni
    PHARMACEUTICALS, 2022, 15 (04)
  • [34] Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
    Woo, C. G.
    Seo, S.
    Kim, S. W.
    Jang, S. J.
    Park, K. S.
    Song, J. Y.
    Lee, B.
    Richards, M. W.
    Bayliss, R.
    Lee, D. H.
    Choi, J.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 791 - 797
  • [35] EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
    Martelli, Maria Paola
    Sozzi, Gabriella
    Hernandez, Luis
    Pettirossi, Valentina
    Navarro, Alba
    Conte, Davide
    Gasparini, Patrizia
    Perrone, Federica
    Modena, Piergiorgio
    Pastorino, Ugo
    Carbone, Antonino
    Fabbri, Alessandra
    Sidoni, Angelo
    Nakamura, Shigeo
    Gambacorta, Marcello
    Luis Fernandez, Pedro
    Ramirez, Jose
    Chan, John K. C.
    Grigioni, Walter Franco
    Campo, Elias
    Pileri, Stefano A.
    Falini, Brunangelo
    AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (02): : 661 - 670
  • [36] EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer Response
    Park, Jae Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (05) : 578 - 578
  • [37] Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Zhang, Yan
    Wang, Yan
    Li, Junling
    Hao, Xuezhi
    Ma, Di
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S377 - S377
  • [38] Isolated central nervous system progression on Crizotinib An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
    Chun, Stephen G.
    Choe, Kevin S.
    Iyengar, Puneeth
    Yordy, John S.
    Timmerman, Robert D.
    CANCER BIOLOGY & THERAPY, 2012, 13 (14) : 1376 - 1383
  • [39] EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer
    Wang, Zhijie
    Zhang, Xuchao
    Bai, Hua
    Zhao, Jun
    Zhuo, Minglei
    An, Tongtong
    Duan, Jianchun
    Yang, Lu
    Wu, Meina
    Wang, Shuhang
    Wang, Yuyan
    Wu, Yilong
    Wang, Jie
    ONCOLOGY, 2012, 83 (05) : 248 - 256
  • [40] Cerivastatin overcomes the acquired resistance to crizotinib in EML4-ALK positive non-small cell lung cancer by controlling YAP activation
    Yun, Miran
    Choi, Hun Mi
    Pyo, Kyoung Ho
    Cho, Byoung Chul
    CANCER RESEARCH, 2017, 77
12345